Home The Active Ingredient Matrix Conjugated Linoleic Acid (c9, t11-CLA)

Formulation Intelligence

Conjugated Linoleic Acid (c9, t11-CLA)

Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Conjugated Linoleic Acid (c9, t11-CLA).

Conjugated Linoleic Acid acts as a dual ligand for PPAR-alpha and PPAR-gamma receptors, modulating lipid metabolism and inhibiting lipoprotein lipase activity to reduce adipocyte volume and improve body composition.

Verified Molecular Profiling (NIH PubChem)

PubChem CID

5280644

Molecular Weight

280.4 g/mol

XLogP3 (Lipophilicity)

7.1

IUPAC Name

(9Z,11E)-octadeca-9,11-dienoic acid

Pharmacokinetic Synergies & Enhancers

Proven Synergy Pairings

  • L-Carnitine for enhanced mitochondrial fatty acid transport
  • Epigallocatechin gallate (EGCG) for synergistic thermogenic fat oxidation

Biological Formulation Enhancers

  • Lecithin for improved lipid emulsification and intestinal micelle formation
  • Piperine for potential inhibition of glucuronidation and metabolic enhancement

Delivery System Constraints & Modeling

Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Conjugated Linoleic Acid (c9, t11-CLA) across standard consumer modalities.

💊 Standard Capsules

As a liquid lipid, CLA requires encapsulation in softgel shells or conversion to a microencapsulated powder to prevent oxidation and leakage in standard two-piece hard capsules.

🍬 Gummy & Pectin Formats

High lipid concentrations in gummy formulations often lead to emulsion instability, resulting in oil migration to the surface and compromised structural integrity of the pectin or gelatin matrix.

🔬 Thin-Film Oral Strips

The high therapeutic dosage requirements (typically 1-3 grams) far exceed the payload capacity of thin-film polymers, which are generally limited to sub-100mg active ingredients.

For Brand Founders

Formulate with Conjugated Linoleic Acid (c9, t11-CLA)

Ready to launch a product featuring Conjugated Linoleic Acid (c9, t11-CLA)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.

Build Science-Backed Formulation

Efficacy Evidence

Maximize Conjugated Linoleic Acid (c9, t11-CLA) Bioavailability

Need absolute proof that your Conjugated Linoleic Acid (c9, t11-CLA) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.

Simulate Bioavailability

For R&D Labs & CDMOs

Conjugated Linoleic Acid (c9, t11-CLA) Degradation Testing

Is your Conjugated Linoleic Acid (c9, t11-CLA) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.

Model Active Degradation